

Covidien (NYSE:COV) and General Electric‘s (NYSE:GE) GE Healthcare subsidiary signed a deal to integrate Covidien’s measurement technologies into GE Healthcare’s patient monitoring devices.
The medical device giants said the 5-year deal includes Covidien’s Nellcor pulse oximetry, INVOS cerebral/somatic oximetry and BIS brain monitoring technologies into GE devices including its CareScape B850 and CareScape B650 monitors.
Sign up to get our free newsletters delivered straight to your inbox
"GE Healthcare is committed to making a broad range of parameter measurements available on our powerful monitoring technology, including GE’s own SpO2 technology," GE monitoring solutions general manager Matthias Weber said in prepared remarks. "Leveraging our 100-year history of designing life-critical devices, we are focused on delivering innovative clinical measurement technology. Such advances have the potential to support improved care, quality, and patient safety."
"The advanced parameter portfolio from Covidien, coupled with GE Healthcare’s patient monitors, supports clinicians in detecting subtle but critical variations in a patient’s status," added Robert White, president of Covidien’s respiratory and monitoring solutions unit. "By delivering the full picture of a patient’s physiological status, patient safety and positive outcomes can be advanced."